1.
Primary biliary cirrhosis
by Carey, Elizabeth J, MD
The Lancet (British edition), 2015, Vol.386 (10003), p.1565-1575
2.
Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis
by Guo, G.‐Y.
Alimentary pharmacology & therapeutics, 2015-07, Vol.42 (2), p.221-230
3.
Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes
by Cheung, A. C.
Alimentary pharmacology & therapeutics, 2016-01, Vol.43 (2), p.283-293
4.
Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid
by Levy, C.
Alimentary pharmacology & therapeutics, 2011-01, Vol.33 (2), p.235-242
5.
Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29‐year cohort study
by Papastergiou, V.
Alimentary pharmacology & therapeutics, 2013-12, Vol.38 (11-12), p.1354-1364
6.
Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA
by Tanaka, Atsushi
Journal of gastroenterology, 2014-09-20, Vol.50 (6), p.675-682
7.
Geoepidemiology and changing mortality in primary biliary cholangitis
by Floreani, Annarosa
Journal of gastroenterology, 2017-04-01, Vol.52 (6), p.655-662
8.
The inter‐relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis
by Dyson, J. K
Alimentary pharmacology & therapeutics, 2016-11, Vol.44 (10), p.1039-1050
9.
Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long‐term outcome and survival
by AL‐CHALABI, T.
Alimentary pharmacology & therapeutics, 2008-07, Vol.28 (2), p.209-220
10.
Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort
by Jones, D E J
Gut, 2006-04, Vol.55 (4), p.536-541
11.
Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid
by Boberg, K. M.
Alimentary pharmacology & therapeutics, 2013-10, Vol.38 (7), p.794-803
12.
Concomitant systemic lupus erythematosus might have a negative impact on the biochemical responses to treatment in patients with primary biliary cholangitis
by Fan, Xiaoli
Clinical rheumatology, 2019-12-06, Vol.39 (3), p.795-803
13.
Canals of Hering loss relates to the progression of the histological stages of primary biliary cirrhosis
by Kakuda, Yuko
Journal of clinical pathology, 2015-02, Vol.68 (2), p.141-147
14.
Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients
by Lammert, Craig
Journal of gastroenterology, 2013-12-08, Vol.49 (10), p.1414-1420
15.
Quantification of the completeness of follow-up
by Clark, Taane G
The Lancet (British edition), 2002-04-13, Vol.359 (9314), p.1309-1310
16.
Primary biliary cirrhosis
by Nguyen, Douglas L., MD
Baillière's best practice & research. Clinical gastroenterology, 2010, Vol.24 (5), p.647-654
17.
Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis
by Azemoto, Nobuaki
Journal of gastroenterology, 2009-04-16, Vol.44 (6), p.630-634
18.
Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis
by Kawata, Kazuhito
Antioxidants & redox signaling, 2010-08-01, Vol.13 (3), p.259-268
19.
Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol
by MASON, A. L.
Alimentary pharmacology & therapeutics, 2008-10, Vol.28 (7), p.886-894
20.
The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis
by Albillos, Agustín
Gut, 2010-07, Vol.59 (7), p.943-952
